114 results about "Histocytochemistry" patented technology

An oncological foundation model is trained with broad, multimodal data to make predictions concerning a variety of different types of cancers. For example, the foundation model may make use of medical images drawn from radiology and pathology, as well as immunohistochemistry data; the presence or absence of biomarkers for particular diagnoses; patient history data; patient demographic data; and other forms of medical data. When using medical images, whole medical images as well as feature sets derived from the medical images may be used. The foundation model may have both causal predictive abilities as well as generative abilities.

Techniques for using combination stain types for machine learning models for digital pathology are described herein. In an example, a system accesses a first image of a sample comprising an immunohistochemistry (IHC) stain for a biomarker. The system accesses a second image of the sample comprising a hematoxylin and eosin (H&E) stain for nuclei. The system can segment tissue regions in the one or more first images and the second image, partitions the tissue regions in the one or more first images and the second image, and extracts features from the set of tiles using a feature extractor. The system can generate, by a machine-learning model, an output classification indicating a first phenotype based on the features extracted from the set of tiles. The machine-learning model can include one or more classifiers and an aggregation model that provides an aggregated output for the set of tiles.

The invention relates to the technical field of medical imaging, in particular to a breast cancer tissue HER2 automatic scoring method and device based on a characteristic curve, and the method comprises the steps: carrying out the reading operation of a full-slice image of immunohistochemical staining; extracting a target region of interest of the full slice image; slicing and screening the target region of interest to obtain a plurality of image slices; calculating a percentage-saturation characteristic curve of each image slice, and extracting characteristic information of the percentage-saturation characteristic curve; based on the feature information of the percentage-saturation feature curve, performing preliminary HER2 scoring on each image slice in combination with a rule base and a logistic regression classification algorithm; and integrating the scoring results of the image slices, and outputting a final HER2 score and a characteristic curve visualization graph. According to the method, the feature curve is combined with the rule base and the logistic regression classification algorithm, so that the objectivity of HER2 scoring is improved, and the problems of subjectivity and low efficiency of manual evaluation are reduced.

Microglial spatial heterogeneity remains a crucial yet poorly studied question in light of potential cell-directed therapies for Alzheimer`s disease (AD). Little is known about the dynamics of spatially distinct microglia states, which are either adjacent or non-associated with the plaque site, and their selective contributions to neurodegeneration in vivo. So far, research has essentially focused on pathology-associated microglia. Here, we combined novel multicolor fluorescence fate mapping, single-cell transcriptional analysis, epigenetic profiling, advanced immunohistochemistry and computational modelling to comprehensively characterize the relation of plaque-associated and non-plaque- associated microglia during neurodegeneration. This approach enabled us to identify and characterize non-plaque-associated microglia as a unique and highly dynamic microglial state in a mouse model of AD. Non-plaque-associated microglia modulate network expansion, quickly adapt to environmental cues and their transition to plaque-associated microglia can be specifically modulated during disease, contrary to their reputation as a passive bystander subpopulation. This description of the dynamics of spatially segregated microglial states and their distinct molecular features may therefore open promising new avenues for state-specific therapeutic interventions during neurodegeneration.

The invention belongs to the technical field of immunohistochemical detection, and discloses a modified composite sealing buffer solution as well as a preparation method and detection application thereof. The modified composite blocking buffer solution comprises a basic buffer system, a composite blocking agent, a nonionic detergent, an endogenous interferent blocking agent and an antibody stabilizer, wherein the basic buffer system provides a stable pH environment and ionic strength; the composite sealing agent firstly occupies a shielding site, and the background is lowered; the nonionic detergent destroys hydrophobic interaction, effectively elute and loosen adsorbed molecules, and promote dissolution of components with relatively strong hydrophobicity; the endogenous interferent blocker can be combined with a receptor firstly, so that non-specific combination of an antibody and the receptor is blocked, and the problem of specific background is solved; the antibody stabilizer can protect the activity of the detection reagent and maintain the stability, and the obtained modified composite sealing buffer solution and the kit thereof have the advantages of multiple cooperative sealing mechanisms, prospective blocking of endogenous interference, improvement of the stability, compatibility and high efficiency of the antibody and the like.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-terminal deoxynucleotidyl transferase (TdT) antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the antibody are respectively shown as SEQ ID NO.8-10. The antibody disclosed by the invention can specifically recognize TdT protein naturally expressed in cells and tissues, has the advantages of high specificity, high affinity, high sensitivity and the like when being used for immunoblotting, immunohistochemistry and other immunodetection systems, is beneficial to reducing false positive and false negative rates in pathological diagnosis, improves the accuracy of immunodiagnosis, and has a good application prospect. The method has wide application potential in the field of immunological detection of living biological samples. In addition, the antibody disclosed by the invention has cross-species reaction characteristics on homologous TdT proteins of human, mice and rats, so that the application scene of the antibody is greatly expanded.

The invention discloses application of jellyfish and snow rabbits in inhibition of ERK phosphorylation level and MAPK pathway and an evaluation method of the jellyfish and snow rabbits, and relates to the technical field of biological medicines.The method comprises the following steps that 1, a treated jellyfish and snow rabbits breast cancer cell group and a control breast cancer cell group are established; and step 2, respectively dividing the two groups of samples in the step 1 into two parts, fixing one part in paraformaldehyde with the mass concentration of 10%, treating, embedding in paraffin for immunohistochemical analysis, and quickly freezing the other part for transcriptomics analysis and the like. According to the invention, UPLC-MS is adopted to determine the main components of SMM, the influence of SMM on breast cancer (BC) is evaluated through in-vivo experiments, in order to deeply clarify the mechanism, network pharmacology and transcriptomics analysis are integrated, finally, immunohistochemistry (IHC) is adopted to verify and explore the exact breast cancer resisting mechanism of SMM, and a scientific basis is provided for potential clinical application of SMM.

The invention relates to a confining liquid and method for reducing background signals in immunohistochemical detection, and belongs to the technical field of immunodetection, and the confining liquid comprises whey protein and an anionic surfactant. By utilizing the confining liquid provided by the invention, background signals generated on a glass slide can be reduced or even eliminated, and the convenience and accuracy of interpretation of an immunohistochemical detection result are improved.

A system and method of categorizing protein expression in biological cells may include receiving a Whole Slide Image (WSI) of an Immunohistochemistry (IHC) assay of cells, stained with two or more color-specific markers, of two or more respective proteins, and applying a stain separation algorithm on the WSI image, to obtain two or more single¬ channel marker images. Based on the two or more marker images, embodiments may generate an enhanced color image, representing expression of the two or more proteins in the assay, and prompt a user to assign at least one label to at least one respective location in the enhanced color image. Embodiments may then use the at least one label as supervisory information, to train a machine-learning (ML)-based classification model, to classify at least one cell -representative location according to categories of expression of the at least two proteins.

The application relates to the field of immunohistochemical staining, in particular to a DAB buffer and a DAB staining solution kit for DAB color development. The application discloses a DAB buffer for DAB color development, and the main components are hydrogen peroxide, nonylphenol polyoxyethylene ether, magnesium sulfate and trisodium citrate. The metal ions in the DAB buffer can enhance the electron transfer speed between DAB and hydrogen peroxide, and improve the color development sensitivity. The nonylphenol polyoxyethylene ether can stabilize the hydrogen peroxide, so that the hydrogen peroxide can be stored for a longer time and the cost is saved. The application further discloses a DAB staining solution kit, which comprises a blocking agent, a reaction enhancer, an enzyme-labeled polymer IgG, a DAB concentrated solution, a DAB buffer and hematoxylin, and the above-mentioned DAB buffer for DAB color development. The DAB staining solution kit of the application can improve the detection sensitivity of immunohistochemical staining, and can also improve the storage stability of the DAB color development solution and reduce the cost.

This invention discloses the application of ITPRIPL1 as a biomarker for the diagnosis or prognosis of gastric cancer. Database analysis revealed high expression of ITPRIPL1 in gastric cancer patients. Immunohistochemical staining of samples from clinically diagnosed gastric cancer patients further validated its high expression in gastric cancer tumor cells, with higher ITPRIPL1 expression levels observed in lower-differentiated tumor tissues. This invention provides a novel biomarker for the diagnosis and prognosis of gastric cancer, offering new ideas and directions for immunotherapy of gastric cancer.

The application discloses a marker combination for predicting the curative effect of liposarcoma based on immunohistochemistry, a screening method and a prediction model thereof and a construction method thereof. The application analyzes the tissue phenotype characteristics of a liposarcoma patient by using an immunohistochemistry technology, combines transcriptomic data, screens a suitable marker combination NCF1, CD27, LST1, CD8A and AOAH based on Lasso-logistic regression, and establishes a more accurate immunotherapy curative effect prediction model for the liposarcoma patient.

The present disclosure provides antibodies that specifically bind to protein tyrosine kinase 7 (PTK7), and methods of using such antibodies. In some cases, the PTK7 antibodies are used in an immunohistochemistry (IHC) assay, which can detect the presence of cells expressing PTK7 in a tissue from a patient.

Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.

The invention belongs to the technical field of biology, and relates to a hybridoma cell strain C8-3-7 and a preparation method thereof. The preservation number of the cell strain C8-3-7 is CCTCC (China Center For Type Culture Collection) No: C202573. The hybridoma cell strain C8-3-7 efficiently expresses the DHX33 antibody and has an infinite proliferation capability. The DHX33 antibody can be specifically combined with DHX33 protein, and can specifically recognize DHX33 protein antigen in ELISA (enzyme-linked immuno sorbent assay) and immunohistochemistry or immunocytochemistry analysis.

The application discloses a BICI scoring system for predicting the curative effect of immunotherapy for metastatic colorectal cancer and application thereof, and belongs to the technical field of biological medicine. The BICI scoring system is based on immunohistochemical detection, integrates four dimensions of angiogenesis, immune checkpoints, TGF-beta signal and immune activation, and is calculated by a formula IHC-BICI=VEGFA+PD-L2+TGFB1x2-CD8 score. Taking 4 points as a cut point, BICI-High and BICI-Low are divided, and a bevacizumab combined with an immune checkpoint inhibitor treatment benefit population is accurately screened. The application also discloses a detection kit containing four specific antibodies, application thereof and a treatment decision method. The scoring system of the application only needs conventional IHC detection, has low cost, excellent prediction effect, is suitable for second-line and above treatment and clinical stratification of MSS / pMMR type metastatic colorectal cancer, and has important clinical application value.

The application discloses application of YW2301 in preparation of a medicine for resisting Burkitt lymphoma, utilizes CCK8 cell activity experiment to detect the inhibition ability of YW2301 on Raji and CA46 cell proliferation, constructs a NON / SCID subcutaneous transplantation tumor model by using a Raji cell line, evaluates the therapeutic significance of YW2301 on Burkitt lymphoma, YW2301 can effectively inhibit the tumorigenicity of Burkitt lymphoma cells and the growth speed of the transplantation tumor, and adopts immunohistochemical staining to detect the ALDH18A1 and c-Myc protein expression in a Burkitt lymphoma transplantation tumor tissue section, YW2301 can effectively down-regulate the ALDH18A1 and c-Myc protein expression in a Burkitt lymphoma tissue, and further proves that YW2301 can be used as a candidate small molecule for targeted treatment of Burkitt lymphoma.

Immunohistochemistry (INC) and in situ hybridization (ISH) methods are used for the targeted detection and localization of biomolecules (e.g., proteins and miRNAs) in tissues or cells, for research applications and clinical applications such as those of pathologists (e.g., biomarker analysis of resected tumors or tumor biopsies). These methods include mass spectrometry imaging (MSI) as a mode for detecting and localizing biomolecules in tissues or cells. The methods employ optically cleavable mass-tagged reagents linked to probes such as antibodies and nucleic acids and used to enable multiplexed immunohistochemistry and in situ hybridization, with MSI as the detection / readout mode. The methods also include multi-omics MSI procedures in which MSI of optically cleavable mass-tagged probes is combined with other MSI modes, such as direct label-free MSI of endogenous biomolecules from biological samples (e.g., tissues).

The use of AST-3424 in the preparation of a drug for treating a patient with hepatocellular carcinoma. A pathological paraffin block or pathological section of ex-vivo liver tumor tissue from the patient with hepatocellular carcinoma is subjected to immunohistochemical staining to detect the protein expression level of an AKR1C3 enzyme, with the detection result showing an H-score greater than or equal to 200; or the pathological paraffin block or pathological section of ex-vivo liver tumor tissue from the patient with hepatocellular carcinoma is subjected to immunohistochemical staining to detect the protein expression level of an AKR1C3 enzyme, with the detection result showing that the sum of percentages of moderate-intensity staining and high-intensity staining is greater than or equal to 70%. The dosing regimen for AST-3424 is as follows: in each 21-day cycle, administration is performed on day 1 and day 8; the initial dose is 6.0 mg / m2 per administration; and the patient will be permitted to receive treatment for a maximum of 34 cycles.

An oncological foundation model is trained with broad, multimodal data to make predictions concerning a variety of different types of cancers. For example, the foundation model may make use of medical images drawn from radiology and pathology, as well as immunohistochemistry data; the presence or absence of biomarkers for particular diagnoses; patient history data; patient demographic data; and other forms of medical data. When using medical images, whole medical images as well as feature sets derived from the medical images may be used. The foundation model may have both causal predictive abilities as well as generative abilities.

The present invention relates to: a composition and kit for immunohistochemistry (IHC) staining, comprising an anti-PAUF monoclonal antibody that specifically binds to a PAUF protein; and an immunohistochemical staining method using same. The present invention exhibits significantly improved staining sensitivity and clarity over conventional PAUF staining methods, thereby providing the advantage of obtaining more accurate and reliable results regarding the expression of the PAUF protein. In addition, the present invention enables accurate staining of a large amount of clinical tissues in a short time by using specialized staining equipment together, thereby providing the advantage of enhancing the reliability of staining results. Accordingly, it is possible to specifically, rapidly, and accurately identify only PAUF within cancer tissues of cancer patients, thereby enabling rapid and efficient cancer diagnosis, and by using this, early cancer diagnosis is possible, thereby enabling early treatment for cancer patients in need of targeted therapy.

A method for pre-treatment identification of cancer patients that respond to anti-CLEVER-1 therapy comprising an administration of an agent capable of binding to CLEVER-1 in a patient. In the method, the presence of CLEVER-1 expressing cells is detected in a tumor sample obtained from a cancer patient, by immunohistochemistry staining by a mouse monoclonal IgG2a kappa STAB-1 antibody (clone 4G9), and a percentage of intra-tumoral CLEVER-1 expressing cells from the total amount of viable intra-tumoral cells present in the stained sample is calculated. A tumor sample which shows substantial percentage of CLEVER-1 expressing intra-tumoral cells is an indication that the cancer patient is responsive to the anti-CLEVER-1 therapy.

A method for training a machine learning model and a computing system performing same, wherein the machine learning model is trained to analyze biological tissue slide images stained by a immunohistochemical staining method for staining tissues expressing specific biomarkers and thus can be used to further elaborately analyze expression levels of biomarkers, etc., whereby a determination can be made on pathological specimen images by analyzing expression levels of biomarkers, etc. A method and system for training a machine learning model using training data, corresponding to immunohistochemically stained images, generated from multiple feature vectors calculated based on various staining intensity criteria.

Provided are chimeric or recombinant antibodies (Abs), or antigen-binding fragments thereof, or monomeric or dimeric antigen-binding proteins capable of specifically binding to human LAG-3 polypeptides, including human LAG-3 polypeptides expressed on the surface of lymphocytes, such as activated T cells or tumor-infiltrating lymphocytes (TILs), that have infiltrated tumors, and methods for producing and using the same. In an alternative embodiment, the chimeric or recombinant antibodies (Abs), or antigen-binding fragments thereof, or monomeric or dimeric antigen-binding proteins as provided herein are used for in vitro diagnosis, e.g., in immunohistochemistry (IHC), to diagnose and / or treat cancer, e.g., bladder cancer, urothelial carcinoma, breast cancer, lung cancer, non-small cell lung cancer, kidney cancer, renal clear cell carcinoma, and / or melanoma or malignant melanoma, due to their ability to specifically bind to activated T cells or tumor-infiltrating lymphocytes that have infiltrated tumors.

The application discloses a method suitable for depigmentation of melanoma tissue in immunohistochemical staining, and the method comprises the following steps: after an antigen repairing step in the immunohistochemical staining process, a depigmentation operation is performed; a hydrogen peroxide methanol solution is used as a depigmentation solution; and the depigmentation is performed through heating incubation, wherein the heating temperature is 55 DEG C to 75 DEG C, the volume fraction of the hydrogen peroxide methanol solution is 5% to 15%, and the incubation time is 10 to 20 minutes. The method simplifies the depigmentation process of melanin, is high in efficiency, and does not affect the morphology of tissue cells and IHC staining while achieving depigmentation, and is suitable for depigmentation of melanin cells of melanoma tissue by using a full-automatic immunohistochemical staining instrument, and can realize automatic depigmentation.

The present application relates to the technical field of biology, and particularly discloses a kind of tyrosine iodination modified PP2A protein monoclonal antibody, preparation method and application.The present application is prepared by tyrosine iodination modified PP2A protein antigen peptide, rabbit is immunized to prepare monoclonal antibody, and is selected by phage display technology, expression vector amplification and ELISA screening, finally obtains a strain of monoclonal antibody R004 that can effectively recognize target.The antibody shows good sensitivity and specificity in immunohistochemistry, cell immunofluorescence and protein immunoblotting.The monoclonal antibody screened in the present application can be used in the detection of tyrosine iodination modification of PP2A protein catalytic subunit 307, and provides support for tumor diagnosis, anti-tumor and neurological disease drug research and development.

The application discloses a red dye solution, a reagent combination and a method for Masson trichrome staining, and belongs to the field of histochemistry technology. The red dye solution comprises 0.4-1.0% of bibracine, 0.4-1.0% of temptation red and 1-2% of acetic acid, and water is used as a solvent, and the red dye solution further comprises 0.05-0.15% of orange G sodium salt; the reagent combination comprises the red dye solution and further comprises a blue dye solution, the blue dye solution comprises 2% of aniline blue, 1-2% of acetic acid, and water is used as a solvent, and the blue dye solution further comprises 0.005-0.03% of fast green, 0.0025-0.015% of brilliant green or 0.005-0.03% of bromocresol green sodium salt. The reagent combination further comprises hematoxylin dye solution, red differentiation agent and blue differentiation agent. The improved red dye solution for Masson trichrome staining provided by the application increases the affinity for muscle fiber dyeing, makes the muscle fiber dyeing more firm, and can still maintain bright red after phosphomolybdic acid differentiation. Meanwhile, the improved blue dye solution makes the collagen fiber dyeing more bright, and the color contrast between the muscle fiber and the collagen fiber is more obvious and easier to distinguish.